Ophthalmic Surg Lasers Imaging Retina. 2020 Apr 1;51(4):S6-S14. doi: 10.3928/23258160-20200401-01.
To estimate the social cost of blindness due to wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) in the United States in 2020.
Excess costs that occur because of blindness were estimated as the difference in costs in blind versus non-blind individuals. Per-patient costs were aggregated using the number of cases of blindness due to wAMD, DME, and PDR projected in 2020.
Associated annual excess direct costs, indirect costs, and quality-adjusted life year loss per blind individual were $4,944, $54,614, and 0.214, respectively. Combining estimates with 246,423 projected cases of blindness due to wAMD, DME, and PDR translated to total societal costs of $20 billion in 2020, estimated to triple by 2050.
Excess social costs associated with blindness in individuals with wAMD, DME, and PDR are substantial, with more than half of the burden attributed to indirect costs. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S6-S14.].
评估 2020 年美国湿性年龄相关性黄斑变性（wAMD）、糖尿病性黄斑水肿（DME）和增生性糖尿病性视网膜病变（PDR）导致失明的社会成本。
因失明而产生的超额成本被估计为盲人与非盲人之间的成本差异。通过 2020 年预计因 wAMD、DME 和 PDR 而导致失明的病例数，对每位患者的成本进行了汇总。
每个失明个体的相关年度超额直接成本、间接成本和质量调整生命年损失分别为 4944 美元、54614 美元和 0.214。将这些估计值与预计因 wAMD、DME 和 PDR 而导致的 246423 例失明病例相结合，意味着 2020 年的总社会成本为 200 亿美元，预计到 2050 年将增加两倍。
wAMD、DME 和 PDR 患者失明相关的社会总成本过高，其中超过一半的负担归因于间接成本。[眼科手术激光成像视网膜。2020;51：S6-S14。]。
